Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVULEN vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ovulen is a combination oral contraceptive containing ethynodiol diacetate (a progestin) and mestranol (an estrogen). It inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. It also increases cervical mucus viscosity and alters endometrial development, impeding sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved indication)
Prevention of pregnancy (FDA-approved)
1 tablet (1 mg ethynodiol diacetate, 50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo or no medication.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinylestradiol: 10-20 hours (mean 17 hours); Dimethisterone: 10-15 hours. Clinical context: Steady state achieved after 3-5 days; elimination prolonged in hepatic impairment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethynodiol diacetate is rapidly metabolized to norethindrone, primarily via hydrolysis, then undergoes reduction, hydroxylation, and conjugation. Mestranol is metabolized to ethinyl estradiol via demethylation, followed by further hydroxylation and conjugation. Both are metabolized by cytochrome P450 enzymes, including CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates), biliary/fecal: 40-50% (enterohepatic circulation).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinylestradiol: 97-98% bound to albumin and sex hormone-binding globulin (SHBG); Dimethisterone: ~90% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinylestradiol: 2-4 L/kg (large Vd indicating extensive tissue distribution, including reproductive tissues and fat); Dimethisterone: 1.5-2.5 L/kg.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinylestradiol 40-60% (first-pass metabolism); Dimethisterone ~70% (oral bioavailability).
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment guidelines available; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential hormonal accumulation.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose reduction established.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Approved only for postmenarchal adolescents; same dosing as adults (1 tablet daily for 21 days with 7-day break). Not indicated before menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. Efficacy and safety in elderly (age >65 years) have not been established.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of cardiovascular events; avoid in women over 35 who smoke.,Increased risk of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction). Discontinue if thrombotic events occur or are suspected.,Elevated blood pressure; monitor regularly.,Gallbladder disease; may worsen or precipitate.,Hepatic neoplasia; rare cases of benign and malignant liver tumors reported.,Carcinoma of breast and reproductive organs; increased risk with long-term use; monitor if history.,Ocular lesions; discontinue if sudden partial or complete loss of vision, proptosis, diplopia, or papilledema occurs.,Glucose intolerance; use with caution in diabetics.,Unscheduled bleeding; rule out pregnancy or other causes.,Depression; discontinue if severe or recurrent.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history).,Cerebrovascular or coronary artery disease (current or history).,Known or suspected breast carcinoma.,Estrogen-dependent neoplasia (known or suspected).,Undiagnosed abnormal genital bleeding.,Pregnancy (known or suspected).,Benign or malignant liver tumor (current or history).,Jaundice or liver disease (acute or chronic) with abnormal liver function, unless improving.,Hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may alter estrogen metabolism but clinical relevance is minimal. Maintain regular diet; no restrictions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm, including cardiovascular anomalies and limb defects. First trimester exposure associated with major congenital malformations; second and third trimester exposure may cause feminization of male fetuses.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in human milk; M/P ratio not established. May reduce milk production and affect infant hormonal development. Contraindicated during breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; contraindicated in pregnancy. No dose adjustments recommended as medication should be discontinued immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Ovulen (ethynodiol diacetate 1 mg + mestranol 0.1 mg) is a first-generation combined oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Use with caution in patients with hypertension, migraine with aura, or liver disease. Breakthrough bleeding is common in the first 3 cycles.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, even if no sexual activity.,Use backup contraception (e.g., condoms) for the first 7 days of starting the pill.,Report sudden severe headache, chest pain, leg swelling, or vision changes immediately.,Smoking increases risk of serious cardiovascular side effects; avoid smoking.,Missed pills increase pregnancy risk; follow missed pill instructions in the patient leaflet.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVULEN vs AFIRMELLE, answered by our medical review team.
OVULEN is a Oral Contraceptive that works by Ovulen is a combination oral contraceptive containing ethynodiol diacetate (a progestin) and mestranol (an estrogen). It inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. It also increases cervical mucus viscosity and alters endometrial development, impeding sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVULEN and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVULEN is: 1 tablet (1 mg ethynodiol diacetate, 50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo or no medication.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVULEN and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVULEN is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm, including cardiovascular anomalies and limb defects. First trimester exposure associated with majo. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.